Actemra/Actemra SC Indications/Uses

Rheumatoid Arthritis (RA) [IV and SC formulations]: Tocilizumab is indicated for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients. Tocilizumab can be used alone or in combination with methotrexate (MTX) and/or other disease-modifying anti-rheumatic drugs (DMARDs). Tocilizumab has been shown to inhibit progression of joint damage as measured by X-ray and to improve physical function.
Giant Cell Arteritis (GCA) [SC formulation only]: Tocilizumab is indicated for the treatment of giant cell arteritis (GCA) in adult patients.
Polyarticular Juvenile Idiopathic Arthritis (pJIA) [IV and SC formulations]: Tocilizumab is indicated for the treatment of active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. Tocilizumab can be given alone or in combination with MTX.
Systemic Juvenile Idiopathic Arthritis (sJIA): Intravenous Formulation: Tocilizumab is indicated for the treatment of active systemic juvenile idiopathic arthritis in patients 2 years of age and older.
Subcutaneous Formulation: Tocilizumab is indicated for the treatment of active systemic juvenile idiopathic arthritis in patients 1 year of age and older.
Tocilizumab IV and SC can be given alone or in combination with MTX.